Navigation Links
Combination of PET/CT tests can expedite diagnosis of lung cancer in a fast-track setting
Date:10/1/2009

Research published in the October 2009 issue of the Journal of Thoracic Oncology has found an effective combination of positron emission tomography (PET)/computed tomography (CT) (PET/CT) tests to diagnose lung cancer in a "fast-tracked" outpatient setting. This novel approach to the diagnosis of lung cancer demonstrated a high level of sensitivity (97%) and accuracy (82%). The fast track model tests patients for lung cancer over the course of one day and could expedite identification and treatment of the disease.

Using the 18F-fluorodeoxyglucose (FDG) imaging technique,with a PET/CT scanner, researchers from The Netherlands Cancer Institute in Amsterdam evaluated 114 patients experiencing pulmonary symptoms and/or abnormal chest x-rays.

Researchers were able to make a final diagnosis for 92 percent of the patients using the fast-tracked model, and determine a malignancy in 84 percent of the patients. These results represent a diagnostic gain of 8 and 7 percent respectively compared to previous techniques.

"Our approach resulted in a fast and accurate diagnosis and allowed for treatment to be initiated without delays." said Dr. Tjeerd S. Aukema of The Netherlands Cancer Institute. "These results suggest that availability of fast track assessment facilities can contribute to appropriate and timely evaluation of lung malignancies."


'/>"/>

Contact: Megan Richter
mrichter@spectrumscience.com
202-587-2556
International Association for the Study of Lung Cancer
Source:Eurekalert

Page: 1

Related medicine news :

1. Promising drug combination may help those with ocular melanoma that has spread
2. Combination therapy reverses effects of portal hypertension in rats
3. Combination vaccines okay for infants, study shows
4. Antidepressants and painkillers - a dangerous combination
5. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Drug combination might offer hope for patients deadly brain tumors
8. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
9. Combination targets: some drugs may work best when they work together
10. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
11. Quality Control: Nissan Quest to Feature micronAir(R) Combination Cabin Air Filters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... 2016 , ... TeaZa® Energy, LLC announces the launch of a ... Tobacco Day . The new flavor—Tropical TeaZa? Energy—will be available to customers exclusively ... The new flavor is best described as a juicy, taste bud takeover. A ...
(Date:5/31/2016)... Penn. (PRWEB) , ... May 31, 2016 , ... ... skills to apply information technology solutions to the healthcare industry, The University of ... graduate-level program offers an accelerated path to a career in rapidly growing field ...
(Date:5/30/2016)... ... May 30, 2016 , ... Zane Benefits, the ... of an original infographic, " Health Benefits Reimbursement Compliance Timeline ." , ... Benefits complies with various federal regulations and reforms. , Navigating the new health ...
(Date:5/29/2016)... (PRWEB) , ... May 29, 2016 , ... "With 30 ... let's the user control the style of their project," said Christina Austin - CEO ... 30 self-animating web-themed intros created exclusively for use in Final Cut Pro X. Pixel ...
(Date:5/28/2016)... ... ... city where’s it’s easy to spot the neon lights of chains serving fast food, one ... a taste for real food. , On May 13, the Best Western Plus ... restaurant focusing on dishes made by hand with wholesome, organic ingredients that are sourced locally ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... May 26, 2016 According to a ... Management Market - U.S. Industry Analysis, Size, Share, Growth, Trends, ... in the U.S. was valued at US$ 5.89 Bn in ... 3.4% from 2015 to 2023 to reach US$ 7.99 Bn ... current and emerging needle free drug delivery devices and the ...
(Date:5/26/2016)... , May 26, 2016 ... With Both Cost Savings and Overall Decreased ... (LSE: BTG), an international specialist healthcare company, has ... the 21st Annual Meeting of ISPOR (International Society ... of hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres ...
(Date:5/26/2016)... Since its commercial introduction in ... life science tool for conducting genetic studies in a ... in its new report that the industry sits on ... by a range of new applications in the clinical ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the Human ...
Breaking Medicine Technology: